Kévin Bigaut

1.4k total citations
28 papers, 671 citations indexed

About

Kévin Bigaut is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Kévin Bigaut has authored 28 papers receiving a total of 671 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pathology and Forensic Medicine, 15 papers in Neurology and 5 papers in Oncology. Recurrent topics in Kévin Bigaut's work include Multiple Sclerosis Research Studies (17 papers), Peripheral Neuropathies and Disorders (12 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Kévin Bigaut is often cited by papers focused on Multiple Sclerosis Research Studies (17 papers), Peripheral Neuropathies and Disorders (12 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). Kévin Bigaut collaborates with scholars based in France, Switzerland and Belgium. Kévin Bigaut's co-authors include J. de Sèze, Nicolas Collongues, Laurent Kremer, Mathilde Goudot, Pierre Labauge, Bruno Stankoff, Romain Deschamps, L. Guilloton, Sandra Vukusic and Céline Louapre and has published in prestigious journals such as PLoS ONE, Annals of Neurology and International Journal of Molecular Sciences.

In The Last Decade

Kévin Bigaut

25 papers receiving 656 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kévin Bigaut France 12 379 374 337 119 66 28 671
Olivier Heinzlef France 10 383 1.0× 205 0.5× 201 0.6× 110 0.9× 41 0.6× 25 604
C. Giannesini France 10 288 0.8× 374 1.0× 256 0.8× 104 0.9× 33 0.5× 15 927
Abir Wahab France 6 226 0.6× 241 0.6× 204 0.6× 70 0.6× 27 0.4× 13 436
Wendy Vargas United States 13 186 0.5× 178 0.5× 140 0.4× 43 0.4× 27 0.4× 35 498
Yael Stern Israel 11 526 1.4× 258 0.7× 170 0.5× 57 0.5× 132 2.0× 15 679
O. Heinzlef France 10 311 0.8× 235 0.6× 64 0.2× 53 0.4× 52 0.8× 18 531
Sara Salama Egypt 10 446 1.2× 473 1.3× 102 0.3× 30 0.3× 25 0.4× 22 637
Sonu M. Brara United States 8 436 1.2× 152 0.4× 66 0.2× 53 0.4× 117 1.8× 11 667
Gautier Bréville Switzerland 9 62 0.2× 146 0.4× 148 0.4× 31 0.3× 62 0.9× 31 313
Pål Berg‐Hansen Norway 16 475 1.3× 148 0.4× 38 0.1× 70 0.6× 118 1.8× 40 699

Countries citing papers authored by Kévin Bigaut

Since Specialization
Citations

This map shows the geographic impact of Kévin Bigaut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kévin Bigaut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kévin Bigaut more than expected).

Fields of papers citing papers by Kévin Bigaut

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kévin Bigaut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kévin Bigaut. The network helps show where Kévin Bigaut may publish in the future.

Co-authorship network of co-authors of Kévin Bigaut

This figure shows the co-authorship network connecting the top 25 collaborators of Kévin Bigaut. A scholar is included among the top collaborators of Kévin Bigaut based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kévin Bigaut. Kévin Bigaut is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sèze, J. de, Chiara Zecca, Giovanni Castelnovo, et al.. (2025). European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment?. Multiple Sclerosis Journal - Experimental Translational and Clinical. 11(1). 3120685010–3120685010. 2 indexed citations
2.
Felten, Renaud, Kévin Bigaut, Laurent Kremer, et al.. (2025). Advancing medical training with augmented reality and haptic feedback simulator: outcomes of a randomized controlled trial on lumbar puncture. BMC Medical Education. 25(1). 1231–1231. 1 indexed citations
3.
Kremer, Laurent, et al.. (2025). Evolution of high-efficacy treatment strategy for relapsing-remitting multiple sclerosis: A real-life observational study. Multiple Sclerosis and Related Disorders. 104. 106690–106690.
4.
Houillier, Caroline, Rénata Ursu, Carole Soussain, et al.. (2024). Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort Study. Annals of Neurology. 97(3). 435–448. 2 indexed citations
5.
Bigaut, Kévin, et al.. (2023). A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study. Revue Neurologique. 179(6). 576–584. 1 indexed citations
6.
Gabriel, Renê Faustino, Cécile Cauquil, David Adams, et al.. (2023). Clinical features and maternal and fetal outcomes in women with Guillain-Barré syndrome in pregnancy. Journal of Neurology. 270(9). 4498–4506. 1 indexed citations
7.
Kremer, Laurent, Marie Fleury, François Sellal, et al.. (2023). Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study. Multiple Sclerosis and Related Disorders. 79. 104942–104942. 7 indexed citations
8.
Bigaut, Kévin, Laurent Kremer, Thibaut Fabacher, et al.. (2022). Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study. Journal of Neurology. 269(6). 3295–3300. 12 indexed citations
9.
Bigaut, Kévin, et al.. (2022). The Translatability of Multiple Sclerosis Animal Models for Biomarkers Discovery and Their Clinical Use. International Journal of Molecular Sciences. 23(19). 11532–11532. 14 indexed citations
10.
Kremer, Laurent, et al.. (2022). Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients. Journal of Neurology. 269(9). 4846–4852. 1 indexed citations
11.
Bigaut, Kévin, Mikaël Cohen, Françoise Durand‐Dubief, et al.. (2021). How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). Multiple Sclerosis and Related Disorders. 53. 103076–103076. 16 indexed citations
12.
Bigaut, Kévin, Laurent Kremer, Thibaut Fabacher, et al.. (2021). Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 Antibodies. Neurology Neuroimmunology & Neuroinflammation. 8(5). 23 indexed citations
13.
Bigaut, Kévin, et al.. (2021). Ophtalmies paranéoplasiques. Journal Français d Ophtalmologie. 45(1). 119–136. 2 indexed citations
14.
Bigaut, Kévin, et al.. (2021). Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection. Revue Neurologique. 177(10). 1237–1240. 21 indexed citations
15.
Sèze, J. de & Kévin Bigaut. (2021). Multiple sclerosis diagnostic criteria: From poser to the 2017 revised McDonald criteria. La Presse Médicale. 50(2). 104089–104089. 4 indexed citations
16.
Bigaut, Kévin, Charles Paul Lambert, Laurent Kremer, et al.. (2020). Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal. 27(2). 232–238. 5 indexed citations
17.
Bigaut, Kévin, Thibaut Fabacher, Laurent Kremer, et al.. (2020). Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort. Multiple Sclerosis Journal. 27(5). 729–741. 11 indexed citations
18.
Louapre, Céline, Nicolas Collongues, Bruno Stankoff, et al.. (2020). Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. Multiple Sclerosis Journal. 26. 49–50. 84 indexed citations
19.
Sèze, J. de & Kévin Bigaut. (2020). Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes. Revue Neurologique. 176(6). 497–499. 2 indexed citations
20.
Bigaut, Kévin, Sophie Achard, Seyyid Baloglu, et al.. (2019). Resting-state functional MRI demonstrates brain network reorganization in neuromyelitis optica spectrum disorder (NMOSD). PLoS ONE. 14(1). e0211465–e0211465. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olivier Heinzlef Breakdown of academic impact, for papers by C. Giannesini Breakdown of academic impact, for papers by Abir Wahab Breakdown of academic impact, for papers by Wendy Vargas Breakdown of academic impact, for papers by Yael Stern Breakdown of academic impact, for papers by O. Heinzlef Breakdown of academic impact, for papers by Sara Salama Breakdown of academic impact, for papers by Sonu M. Brara Breakdown of academic impact, for papers by Gautier Bréville Breakdown of academic impact, for papers by Pål Berg‐Hansen
Rankless by CCL
2026